Imlunestrant with or without abemaciclib in advanced breast cancer: Updated efficacy results from the phase III EMBER-3 trial

Last Updated: Wednesday, July 22, 2026

The EMBER-3 trial evaluated imlunestrant alone versus standard of care (SOC) and versus imlunestrant plus abemaciclib in previously treated patients with ER+ HER2- advanced breast cancer. In patients with ESR1 mutations, imlunestrant demonstrated sustained progression-free survival (PFS) benefit and a numerically longer median overall survival (OS) versus SOC. In all patients, the addition of abemaciclib extended PFS to 10.9 months and delayed time to chemotherapy, although OS data remain immature.

Annals of Oncology

ESMO Open

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the phase III EMBER-3 trial

Cancers

Body mass index and outcomes in HR+/HER2- metastatic breast cancer treated with palbociclib: Insights from a national real-world study

Journal of Clinical Medicine

Is genetic testing of HER2-negative metastatic breast cancer patients implemented into clinical practice? A retrospective analysis

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors

Cancer Treatment Reviews

Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis

Annals of Oncology